Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease

Expert Review of Neurotherapeutics

Volumn 12, Issue 2, 2012, Pages 179-190

  Morales Vidal, Sarkis ^a   Schneck, Michael J ^a   Flaster, Murray ^a   Biller, José ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

apixaban; dabigatran; direct factor Xa inhibitors; direct thrombin inhibitors; rivaroxaban; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; HEART ATRIUM FIBRILLATION; MORBIDITY; MORTALITY; REVIEW; UNITED STATES;

ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; STROKE; THIOPHENES;

EID: 84856619789     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.185     Document Type: Review

References (42)

1. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040 (2005). (Pubitemid 41262337)
2. Fuster V, Rydén LE, Cannom DS, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 57(11), e101-e98 (2011).
3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrialfibrillation and flutter in the United States. Am. J. Cardiol. 104(11), 1534-1539 (2009).
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370-2375 (2001). (Pubitemid 32424106)
5. Pérez-Gómez F, Iriarte JA, Zumalde J, et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. Eur. Heart J. 28(8), 996-1003 (2007). (Pubitemid 47343894)
6. Kim YD, Cha MJ, Kim J, et al. Ischaemic cardiovascular mortality in patients with non-valvular atrial fibrillation according to CHADS2 score. Thromb. Haemost. 105(4), 712-720 (2011).
7. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36, 1115-1119 (2005). (Pubitemid 40803473)
8. Pisters R, Lane DA, Nieuwelaat R, et al. A novel, user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 138, 1093-1100 (2010).
9. Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118(17), 2029-2037(2008).
10. Matchar DB, Samsa GP, Cohen SJ, et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am. J. Med. 113(1), 42-51 (2002). (Pubitemid 34775159)
11. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W), a randomized controlled trial. Lancet 367, 1903-1912 (2006).
12. Francis CW, Berkowitz SD, Comp PC, et al. The EXULT A Study Group. Comparison of ximelagatran with warfarin the prevention of venous thrombo embolism after total knee replacement. N. Engl. J. Med. 349, 1703-1712 (2003). (Pubitemid 37315007)
13. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III), randomized controlled trial. Lancet 362, 1691-1698 (2003). (Pubitemid 37468318)
14. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100(9), 1419-1426 (2007). (Pubitemid 47576022)
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009); erratum in: N. Engl. J. Med. 363(19), 1877 (2010).
16. Pradaxa (dabigatran etexilate), prescribing information. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA (2010).
17. Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745), 975-983 (2010).
18. Beasley BN, Unger EF, Temple R. Anticoagulant options -why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med. 364(19), 1788-1790 (2011).
19. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N. Engl. J. Med. 365, 2039-2040 (2011).
20. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011).
21. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364(9), 806-817 (2011).
22. Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 159(3), 331-339 (2010).
23. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981-992 (2011).
24. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective Anticoagulation with Factor Xa Next Generation in Atrialfibrillation-Thrombolysis in Myocardial Infarction Study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 160(4), 635-641 (2010).
25. Ezekowitz M, Diaz R, Dorian P, et al. Randomized clinical trial of three doses of a long-acting oral factor Xa inhibitor betrixaban, in patients with atrial fibrillation. Presented at: The American College of Cardiology's 59th Annual Scientific Session. Atlanta, Georgia, USA, 14-16 March 2010.
26. Gorina E, Connolly S, Diaz R, et al. Phase II randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with warfarin in AF. EXPLORE-Xa. Presented at: Presented at: The American College of Cardiology's 59th Annual Scientific Session. Atlanta, Georgia, USA, 14-16 March 2010.
27. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352(13), 1305-1316 (2005).
28. Kasner SE, Lynn MJ, Chimowitz MI, et al. Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology 67(7), 1275-1278 (2006). (Pubitemid 44563843)
29. Hankey GJ. Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Stroke 33(6), 1723-1726 (2002). (Pubitemid 34619986)
30. Sacco RL, Prabhakaran S, Thompson JL, et al. WARSS Investigators. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin-Aspirin Recurrent Stroke Study. Cerebrovasc. Dis. 22(1), 4-12 (2006). (Pubitemid 43875154)
31. Cervical Artery Dissection in Stroke Study Trial Investigators. Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS). Int. J. Stroke 2(4), 292-296 (2007).
32. Ferro JM, Canhão P, Stam J, et al. ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35(3), 664-670 (2004). (Pubitemid 38280838)
33. Coutinho JM, Ferro JM, Canhão P, et al. ISCVT Investigators. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke 41(11), 2575-2580 (2010).
34. Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int. J. Med. Sci. 7(1), 15-18 (2009).
35. Pullicino P, Thompson JL, Barton B, et al. WARCEF Investigators. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF), rationale, objectives, and design. J. Card. Fail. 12(1), 39-46 (2006). (Pubitemid 43267750)
36. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann. Intern. Med. 154(1), 1-11 (2011).
37. Rhea JM, Molinaro RJ. Direct thrombin inhibitors: clinical uses, mechanism of action, and laboratory measurement. MLO Med. Lab. Obs. 43(8), 20-24 (2011).
38. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy 31(12), 1175-1191 (2011).
39. AstraZeneca Pharmaceuticals. Successful outcome to the mutual recognition procedure for Exanta (ximelagatran) in Europe. www.astrazeneca.com/Media/Press- releases/Article/20040505-SUCCESSFUL-OUTCOME-OF-THE-MUTUAL-RECOGNITION-PROCEDUR
40. FDA. Cardiovascular and Renal Drugs Advisory Committee testimony. www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4069T1.pdf
41. AstraZeneca clinical trials. www.astrazenecaclinicaltrials.com/other- drug-products/discontinued-products/exanta/
42. Sandy Walsh. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm